RGLS Research and Charts

RGLS - Regulus Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-05-09)

Last 7.87	Change ⇑ +0.02 (+0.25%)	Volume 1,645,232
	Open 7.83	High 7.92	Low 7.81

8EMA (Daily) 6.99	40EMA (Daily) 3.70	50EMA (Daily) 3.33	STO (Daily) 94.438	MACD Hist (Daily) 0.827
8EMA (Weekly) 4.248	40EMA (Weekly) 2.21	50EMA (Weekly) 2.09	STO (Weekly) 90.402	MACD Hist (Weekly) 1.427


Company Profile
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.